Date: 2014-07-30
Type of information: IPO
Company: Bio Blast Pharma (Israel)
Investors:
Amount: $ 35.2 million (€ 26.1 million)
Funding type: IPO
Planned used:
Others: * On July 30, 2014, Bio Blast Pharma, a clinical-stage biotechnology company committed to developing therapies for patients with rare and ultra-rare genetic diseases, announced the pricing of its initial public offering of 3,200,000 ordinary shares at an initial public offering price of $11.00 per share. The gross proceeds to BioBlast from the initial public offering are expected to be $35,200,000, before underwriting discounts and commissions and other estimated offering expenses. BioBlast has granted the underwriters a 30-day option to purchase up to 480,000 additional ordinary shares to cover over-allotments, if any, at the public offering price less the underwriting discount. The ordinary shares have been approved for listing on The NASDAQ Global Market under the ticker symbol \"ORPN\" and are expected to begin trading on July 31, 2014. The offering is expected to close on August 5, 2014, subject to customary closing conditions.Oppenheimer & Co. and Roth Capital Partners are acting as joint book-running managers for the offering. BTIG is acting as co-manager.
Therapeutic area: Rare diseases - Genetic diseases
